Bruce G. Allen Investments LLC Sells 927 Shares of Sanofi (NASDAQ:SNY)

Bruce G. Allen Investments LLC cut its holdings in Sanofi (NASDAQ:SNY) by 15.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 5,219 shares of the company’s stock after selling 927 shares during the quarter. Bruce G. Allen Investments LLC’s holdings in Sanofi were worth $289,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of SNY. Gradient Investments LLC increased its position in shares of Sanofi by 2.1% during the first quarter. Gradient Investments LLC now owns 9,764 shares of the company’s stock worth $542,000 after acquiring an additional 200 shares in the last quarter. Providence Capital Advisors LLC boosted its stake in Sanofi by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock worth $2,653,000 after purchasing an additional 201 shares during the period. Bailard Inc. boosted its stake in Sanofi by 1.4% in the 4th quarter. Bailard Inc. now owns 16,359 shares of the company’s stock worth $789,000 after purchasing an additional 220 shares during the period. Beacon Financial Group increased its holdings in Sanofi by 1.6% during the 1st quarter. Beacon Financial Group now owns 14,398 shares of the company’s stock worth $799,000 after purchasing an additional 222 shares in the last quarter. Finally, AdvisorNet Financial Inc raised its stake in shares of Sanofi by 16.4% in the 1st quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company’s stock valued at $89,000 after purchasing an additional 227 shares during the period. 14.04% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. The Goldman Sachs Group began coverage on Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price on the stock. BNP Paribas began coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price target for the company. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a report on Monday, June 2nd. Finally, Guggenheim reissued a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $61.50.

Sanofi Stock Up 1.4%

NASDAQ:SNY opened at $50.47 on Monday. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The firm has a market capitalization of $123.78 billion, a price-to-earnings ratio of 20.27, a price-to-earnings-growth ratio of 1.01 and a beta of 0.50. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock’s 50 day moving average price is $51.71 and its two-hundred day moving average price is $52.00.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business had revenue of $10.41 billion during the quarter, compared to analysts’ expectations of $9.79 billion. During the same period last year, the business earned $1.78 earnings per share. The firm’s revenue was down 11.0% on a year-over-year basis. Equities research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. The ex-dividend date is Friday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi’s payout ratio is currently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.